HBM Healthcare

HBM Healthcare Investments participated in CellCentric's £170m Series D in May 2026, alongside Venrock Healthcare, Pfizer, Fidelity, Sofinnova Partners, and others. CellCentric's inobrodib programme for multiple myeloma and prostate cancer sits within HBM's clinical-stage oncology focus.

HBM Healthcare Investments is a Swiss investment company listed on the SIX Swiss Exchange, founded in 2001 and headquartered in Zug, Switzerland. It invests in private and public healthcare and biotech companies at clinical stage, with a diversified portfolio across Europe and the US. As a listed closed-end vehicle, HBM provides retail and institutional investors access to a diversified portfolio of clinical-stage biotech companies. Its co-investment in CellCentric alongside institutional VCs and a pharma strategic (Pfizer) signals confidence in the clinical trajectory toward a major trial readout.